X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Newspaper Article (91) 91
Journal Article (88) 88
Publication (18) 18
Book / eBook (4) 4
Book Chapter (3) 3
Dissertation (3) 3
Patent (2) 2
Conference Proceeding (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (32) 32
trials (31) 31
index medicus (29) 29
male (21) 21
female (20) 20
murders & murder attempts (19) 19
oncology (19) 19
middle aged (16) 16
adult (14) 14
attorneys (14) 14
aged (13) 13
article (12) 12
kidnapping (12) 12
capital punishment (11) 11
chemotherapy (9) 9
criminal investigations (9) 9
gemcitabine (9) 9
aged, 80 and over (8) 8
antineoplastic agents - therapeutic use (8) 8
care and treatment (7) 7
mutation (7) 7
analysis (6) 6
court hearings & proceedings (6) 6
medicine & public health (6) 6
pancreatic cancer (6) 6
therapy (6) 6
treatment outcome (6) 6
abridged index medicus (5) 5
cancer (5) 5
coaches & managers (5) 5
diabetes (5) 5
evidence (5) 5
kras (5) 5
medicine, general & internal (5) 5
neoplasm staging (5) 5
pancreatic neoplasms - drug therapy (5) 5
professional soccer (5) 5
proto-oncogene proteins b-raf - genetics (5) 5
radiotherapy (5) 5
research (5) 5
risk factors (5) 5
rugby (5) 5
sheriffs (5) 5
social networks (5) 5
state court decisions (5) 5
studies (5) 5
surgery (5) 5
tournaments & championships (5) 5
women (5) 5
adenocarcinoma (4) 4
cells (4) 4
chemoradiotherapy (4) 4
cholangiocarcinoma (4) 4
colorectal-cancer (4) 4
disease-free survival (4) 4
dosage and administration (4) 4
drug therapy (4) 4
folfirinox (4) 4
genetic aspects (4) 4
metastasis (4) 4
mutations (4) 4
outcomes (4) 4
pancreatic neoplasms - pathology (4) 4
patients (4) 4
testimony (4) 4
trial (4) 4
usage (4) 4
adolescent (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antineoplastic agents - adverse effects (3) 3
antineoplastic agents - pharmacology (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
biomarker (3) 3
braf (3) 3
camptothecin - administration & dosage (3) 3
camptothecin - analogs & derivatives (3) 3
carcinoma (3) 3
case studies (3) 3
cellular telephones (3) 3
chemoradiation (3) 3
colorectal cancer (3) 3
complications and side effects (3) 3
criminal sentences (3) 3
deaths (3) 3
efficacy (3) 3
egfr (3) 3
endocrinology & metabolism (3) 3
families & family life (3) 3
federal court decisions (3) 3
firearms (3) 3
fluorouracil - administration & dosage (3) 3
health aspects (3) 3
inhibition (3) 3
law enforcement (3) 3
leucovorin - administration & dosage (3) 3
organoplatinum compounds - administration & dosage (3) 3
phase-ii (3) 3
population (3) 3
rape (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 6, pp. 801 - 810
Journal Article
Annals of Surgery, ISSN 0003-4932, 2015, Volume 261, Issue 1, pp. 12 - 17
Purpose: On the basis of the ACCORD trial, FOLFIRINOX is effective in metastatic pancreatic adenocarcinoma (PDAC), making it a rational choice for locally... 
Neoadjuvant therapy | Chemotherapy | FOLFIRINOX | PDAC | Surgery | Downstaging | Pancreas cancer | Pancreatic adenocarcinoma | 1423 PANCREATICODUODENECTOMIES | pancreatic adenocarcinoma | SURGEONS CONTRIBUTION | LONG-TERM SURVIVAL | MINIMAL POSTOPERATIVE COMPLICATIONS | ADENOCARCINOMA | PHASE-II | chemotherapy | neoadjuvant therapy | GEMCITABINE | CHEMORADIATION | pancreas cancer | RADIOTHERAPY | SINGLE-INSTITUTION EXPERIENCE | downstaging | surgery | Leucovorin - administration & dosage | Adenocarcinoma - pathology | Humans | Middle Aged | Male | Pancreaticoduodenectomy | Chemoradiotherapy | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Neoadjuvant Therapy | Pancreatic Neoplasms - mortality | Retrospective Studies | Imaging, Three-Dimensional | Camptothecin - analogs & derivatives | Spiral Cone-Beam Computed Tomography | Pancreatic Neoplasms - pathology | Pancreatectomy | Treatment Outcome | Disease-Free Survival | Magnetic Resonance Imaging | Adenocarcinoma - therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Adenocarcinoma - diagnostic imaging | Neoplasm Staging | Pancreatic Neoplasms - diagnostic imaging | Adenocarcinoma - mortality | Pancreatic Neoplasms - therapy
Journal Article
Cancer Discovery, ISSN 2159-8274, 04/2015, Volume 5, Issue 4, pp. 358 - 367
Journal Article
Journal Article
Nature Reviews. Clinical Oncology, ISSN 1759-4774, 01/2010, Volume 7, Issue 1, p. 7
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 12, pp. 1255 - 1257
Journal Article
Journal Article
Journal of Hepato-Biliary-Pancreatic Sciences, ISSN 1868-6974, 7/2012, Volume 19, Issue 4, pp. 326 - 336
Biliary tract cancers (BTCs) are a heterogeneous group of malignancies, with a historically poor prognosis as a whole. Until recently, the development of... 
Diagnostic Radiology | Epidermal growth factor receptor (EGFR) | Vascular endothelial growth factor (VEGF) | Mitogen-activated protein kinase (MAPK) | Internal Medicine | Pathology | Medicine & Public Health | Gastroenterology | Abdominal Surgery | Phosphatidylinositol-3-kinase (PI3K)-targeted therapy | Surgical Oncology | Cholangiocarcinoma | Gallbladder carcinoma | mitogen‐activated protein kinase (MAPK) | gallbladder carcinoma | epidermal growth factor receptor (EGFR) | cholangiocarcinoma | phosphatidylinositol‐3‐kinase (PI3K)‐targeted therapy | vascular endothelial growth factor (vegf) | Mitogenactivated protein kinase (MAPK) | PLUS GEMCITABINE | SURGERY | INTRAHEPATIC CHOLANGIOCARCINOMA | GROWTH-FACTOR-RECEPTOR | MICROSATELLITE INSTABILITY | ACQUIRED-RESISTANCE | PHASE-II | GALLBLADDER CANCER | K-RAS MUTATION | C-MET | PROGNOSTIC-SIGNIFICANCE | GASTROENTEROLOGY & HEPATOLOGY | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Humans | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Molecular Targeted Therapy | Bevacizumab | Receptor, Epidermal Growth Factor - metabolism | Angiogenesis Inhibitors - therapeutic use | Bile Ducts, Intrahepatic | Biliary Tract Neoplasms - drug therapy | Biliary Tract Neoplasms - genetics | Cetuximab | TOR Serine-Threonine Kinases - drug effects | Bile Duct Neoplasms - drug therapy | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Signal Transduction | Treatment Outcome | Phosphatidylinositol 3-Kinases - genetics | Class I Phosphatidylinositol 3-Kinases | Gallbladder Neoplasms - drug therapy | Cholangiocarcinoma - drug therapy | Mitogen-Activated Protein Kinases - antagonists & inhibitors | Proto-Oncogene Proteins B-raf - drug effects | Quinazolines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors
Journal Article
Investigational New Drugs, ISSN 0167-6997, 08/2012, Volume 30, Issue 4, p. 1614
  Background MKC-1 is an orally available cell cycle inhibitor with downstream targets that include tubulin and the importin-β family. We conducted an... 
Antimitotic agents | Complications and side effects | Pancreatic cancer | Dosage and administration | Genetic aspects | Antineoplastic agents | Drug therapy | Studies | Clinical trials | Inhibitor drugs | Patients
Journal Article
Cancer Discovery, ISSN 2159-8274, 2017, Volume 7, Issue 6, pp. 610 - 619
Preclinical evidence suggests that concomitant BRAF and EGFR inhibition leads to sustained suppression of MAPK signaling and suppressed tumor growth in... 
COLON-CANCER | BIOMARKERS | WILD-TYPE | INHIBITION | ONCOLOGY | RAF | KRAS | FLUOROURACIL | GENE COPY NUMBER | MAPK PATHWAY | EGFR | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Thiazoles - administration & dosage | Antineoplastic Agents - therapeutic use | Carbamates - administration & dosage | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Cetuximab - therapeutic use | Thiazoles - adverse effects | Cetuximab - adverse effects | Antineoplastic Agents - adverse effects | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Sulfonamides - adverse effects | Carbamates - adverse effects | Cetuximab - administration & dosage | Aged | Mutation | Carbamates - therapeutic use | Sulfonamides - administration & dosage | Index Medicus
Journal Article
Journal Article
Current Colorectal Cancer Reports, ISSN 1556-3790, 6/2012, Volume 8, Issue 2, pp. 143 - 151
The use of neoadjuvant strategies for patients with hepatic-limited metastatic colorectal cancer has demonstrated promise for improving the outcomes of these... 
Biomarker | Oncology | Neoadjuvant | BRAF | Bevacizumab | Colorectal-liver metastases (CLM) | Medicine & Public Health | Colorectal Surgery | KRAS | Circulating tumor cells | Cetuximab | Colorectal cancer (CRC) | Proctology | Liver cancer | Care and treatment | Metastasis | Angiogenesis inhibitors | Colorectal cancer
Journal Article